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Background: Biologic activities of functional mediators activate downstream transducers regulating inflammation
and carcinogenesis. Correlation among mediators (IL-6, IL-27, TNF-α, and VEGF) with STAT proteins at diverse
clinical-pathologic stages of hepatocellular carcinoma (HCC) remains limited.
Methods: Serum mediators assayed from 147 untreated HCC cases (HCC-total group) included 70 HBV-infected
(HCC-HBV group), 64 HCV-infected (HCC-HCV group), and 13 without HBV-/HCV-infection (HCC-NBNC group).
Another 156 non-HCC individuals comprised 54 healthy individuals (HG) and 102 chronic hepatitis patients
(CH-total group) as control group. To correlate with serum mediators, 86-paired liver tissues (CH: 52 and HCC:
34 cases) served for p-STATs proteins immunostain.
Results: Although four mediators (IL-6, IL-27, TNF-α, and VEGF) significantly over-expressed, IL-6 presented the
strongest correlation in HCC-total versus CH-total or HG groups (HCC-total versus CH-total: P < 0.001; HCC-total
versus HG: P < 0.001). Over-expressed IL-6 concentration linked with poor liver function (Albumin: r = −0.383, P <
0.001; Bilirubin: r = 0.280, P = 0.001; INR: r = 0.299, P < 0.001; AST: 0.212, P = 0.016), tumor progression (TNM system:
r = 0.370; P < 0.001), clinical condition severity (BCLC system: r = 0.471; P < 0.001; terminal- versus early-stage HCC,
P = 0.001; advanced- versus early-stage HCC, P = 0.007; terminal- versus intermediate- stage HCC P = 0.003;
advanced- versus intermediate-stage HCC P = 0.019), and 6-month mortality (P = 0.024). Likewise, serum IL-6 (r = 0.501,
P = 0.003) as compared to IL-27 (r = 0.052, P = 0.770), TNF-α (r = 0.019, P = 0.917), and VEGF (r = 0.096, P = 0.595) expression
reflected positive correlation with activation of tissues p-STAT3 rather than p-STAT1.
Conclusions: Serum IL-6, through p-STAT3 rather than p-STAT1 signal pathway, affected hepatic function, tumor
progression, and determine HCC patient survival.
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Worldwide, 711,000 new hepatocellular carcinoma (HCC)
cases are diagnosed per annum, with 679,000 eventually
dying [1]. Hepatitis B (HBV) and C virus (HCV) infections
both contribute as leading causes [2,3]. Diagnostic and
therapeutic modalities have emerged in clinical scenarios;
to date, these prove inadequate due to obstacles of vascu-
lar invasion or extra-hepatic metastases [4-6]. Biochemical
candidates have thus been identified by cell line or animal
studies that contribute to early development and distant
spread of cancer cells, but are rarely available in clinical
applications [7-11]. The possibility could arise from the
complicated interactions between tumor and host micro-
environment in the real world. Therefore, through clinical
evidence, to find the effective biomarkers and further clar-
ify interactions with their downstream signaling targets
should help greatly when evaluating actual roles in clinical
settings and finally devising effective therapeutic strategies
to solve this global problem.
Among well-recognized mediators, wide-ranging bio-
logical activities by IL-6, IL-27, TNF-α, and VEGF have
been implicated in regulating inflammation and/or car-
cinogenesis [12-16]. In hepatic study, multifunctional
cytokine IL-6 can stimulate hepatocyte proliferation and
regeneration as well as growth modulation and tumor
differentiation. High IL-6 levels might reflect more active
hepatic necro-inflammation and associate with severity
of disease [17-19]. Interleukin-27 (IL-27), a heterodi-
meric cytokine belonging to the IL-12 family, not only
act on hepatocytes against viral activity but also curb
tumor proliferation [20,21]. Tumor necrosis factor-alpha
(TNF-α), regarded as a pro-inflammatory cytokine, is
actively involved in regulation of portal hypertension
and carcinogenesis [22-24]. In contrast to multifunc-
tional activities of IL-6 and IL-27 and TNF-α in differ-
ent stages of liver disease, vascular endothelial growth
factor (VEGF), an essential regulator during angiogenesis
rather than inflammatory process [15,25], triggers blood
vessel growth for nutrition of cancer cells and affects sur-
vival in advanced HCC cases [26-28] . However, biologic
function of these mediators is mediated by signaling
pathways. Among them, signal transducers and activators
of transcription (STATs) have been observed as essential
components linking cytokine signals to transcriptional
events that lead to cell proliferation, protection from
apoptosis, tumorigenesis, and increased metastatic poten-
tial in various cells, including cancer [12,16,29-32]. Yet the
relationship and biologic effect of functional mediators
with STATs proteins is limited mostly to study of cell lines,
animal models, or non-HCC patients, and is poorly under-
stood in clinical HCC patients.
To elucidate clinical roles and relationships of IL-6,
IL-27, TNF-α, and VEGF with STATs proteins at differ-
ent clinical-pathological stages of HCC, we conductedthis cohort study. Findings on biological mechanisms of
these molecules and their interrelations with cancer
might increase our understanding to create new thera-
peutic modalities for managing liver tumors.
Methods
Patients
With informed consent, 303 patients with well-charac-
terized clinical conditions for serum mediators assay, in-
cluding 147 naïve HCC patients (HCC-total group), 102
chronic hepatitis patients (CH-total group) and 54
healthy persons (HG) were enrolled in China Medical
University Hospital at Taichung, Taiwan. As per clinical
serological diagnoses, HCC-total patients were sub-
grouped as: (1) 70 with positive HBsAg for longer than
6 months (HCC-HBV), (2) 64 with positive anti-HCV
Ab for more than 6 months (HCC-HCV), and (3) 13
with negative HBsAg and anti-HCV markers (HCC-
NBNC group). Hepatitis patients without HCC but with
positive HBsAg or anti-HCV marker for longer than
6 months were enrolled as the chronic hepatitis (CH)
group: 28 HBV- and 74 HCV-infected. Those, without
HCC and negative HBsAg/ anti-HCV marker, were en-
rolled as a healthy group (HG). Another 86-paired liver
tissues, including 34 HCC (12 HBV, 17 HCV, and 5
NBNC cases) plus 52 CH (18 HBV and 34 HCV cases)
served for immunostain of STAT1 (p-STAT1) and STAT3
phosphorylation (p-STAT3).
The HCC was defined as: (1) histopathology proven by
liver biopsy, or (2) image such as abdomen computer-
ized tomography showing HCC diagnosis. Classification
of HCC severity accorded with TNM and the Barcelona
Clinic Liver Cancer (BCLC) staging system, as did treat-
ment of all HCC cases. Additionally, according to me-
dian HCC survival [11] as well as rate of BCLC severity
and mortality in our study, we selected 6-month mortal-
ity as cut-off point and evaluated the correlation with
four mediators. Patients with (1) co-infection or super-
infection (HBV or HCV); (2) prior antiviral agents like
interferon or nucleoside analogues, immunomodulatory
or anti-tumour agent; (3) autoimmune hepatitis or drug-
induced liver disease; or (4) acute inflammation within
two weeks, such as gout arthritis, were excluded. Proce-
dures conformed to ethical standards of the responsible
Committee on Human Experimentation (institutional
and national) and with the 1975 Helsinki Declaration, as
revised in 2008. The Institutional Review Board of China
Medical University Hospital also approved this study.
Serological virus markers and liver biochemical assays
methodology
Serum HBV markers, anti-HCV antibodies, HBV DNA,
and HCV RNA levels were assessed by commercial en-
zyme immunoassay (AxSYM, Abbott, North Chicago, IL;
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cor HCV Monitor 2.0; Roche Diagnostics, Branchburg, NJ).
Albumin, AFP, ALT, AST, bilirubin, coagulation, and cre-
atinine were tested by autoanalyzer (TBA-30FR, Toshiba;
Tokyo, Japan).
Estimation of serum mediators and tissue
immunohistochemistry
Venous blood samples were obtained from a peripheral
vein of all enrolled cases and immediately centrifuged,
plasma stored at −80 °C. Quantification of IL-6, IL-27,
TNF-α and VEGF by specific ELISA used commercially
available kits within two weeks (IL-6, IL-27, and TNF-α
used by eBioscience, San Diego, CA; VEGF used by
Antigenix American, Huntington Station, NY). Results
were expressed in picograms per milliliter (pg/ml), liver
tissues fixed in 10% formalin and embedded in paraffin.
Blocks were sectioned at 4 μm for each tissue and three
pieces of each specimen stained, including one without
and two with phosphorylation according to standard
protocol (Cell Signaling Technology, Inc. 3 Trask Lane,
Danvers, MA). The p-STAT1 and p-STAT3 immuno-
staining was assessed quantitatively by counting the total
number of positively stained cytoplasma and nuclei of
hepatocytes per 10 high-power fields (×400 magnifications)
microscopically from each specimen. Positive immunostain
was considered when ≧10% nuclei or cytoplasma of hepato-
cytes were stained [33]. The immunoreactivity expression
was categorized as Level I (mean <10% nuclei or cyto-
plasma of hepatocytes stained, II (mean ≧10% to <25%
nuclei or cytoplasma of hepatocytes stained, or III (mean
≧25% nuclei or cytoplasma of hepatocytes stained).
Statistical analysis
Baseline data were expressed as mean ± standard deviation
(Table) and mean ± standard error deviation (figures and me-
diators), each group of experiments repeated at least twice
to confirm data. Continuous variables were assessed by Stu-
dent t-test and Pearson correlation, data analyzed by SPSS
version 17.0 for Microsoft Windows (SPSS, Chicago, IL).
Two-sided P-value < 0.05 indicated statistical significance.
Results
Patients’ demographic and clinical characteristics
Table 1 shows baseline characteristics of 147 HCC, 102 hepa-
titis cases, and 54 healthy persons. HCC-total patients were
older than those in CH-total and HG groups (65.36 ± 11.68
versus 50.20 ± 14.53 versus 42.87 ± 13.35 years respectively),
which was compatible with distribution of liver diseases.
Compared to healthy group (HG), four mediators besides
VEGF presented significantly in CH group
In HBV- or HCV-infected liver disease, IL-6, IL-27, and
TNF-α presented significant expression in CH-totalgroup than HG (3.79 ± 1.40 versus 0.46 ± 0.10 pg/ml in
IL-6, P = 0.02; 164.19 ± 33.43 versus 9.83 ± 3.26 pg/ml in
IL-27, P < 0.001; 75.62 ± 28.14 versus 1.76 ± 1.49 pg/ml
in TNF-α, P = 0.011 respectively) (Figure 1).
Among four mediators, over-expression of IL-6 presented
the strongest correlation with HCC-total and separate
HCC groups than healthy (HG) or CH-total group
While hepatocarcinogenesis, four mediators presented
predominant expression in HCC-total group as com-
pared to HG (19.70 ± 3.28 versus 0.46 ± 0.10 pg/ml in
IL-6, P < 0.001; 298.46 ± 69.23 versus 9.83 ± 3.26 pg/ml
in IL-27, P < 0.001; 65.40 ± 23.82 versus 1.76 ± 1.49 pg/
ml in TNF-α, P = 0.009; 14.12 ± 2.91 versus 0.40 ±
0.07 pg/ml in VEGF, P < 0.001 respectively) but TNF-α
failed in CH group (19.70 ± 3.28 versus 3.79 ± 1.40 pg/
ml in IL-6, P < 0.001; 298.46 ± 69.23 versus 164.19 ±
33.43 pg/ml in IL-27, P = 0.040; 65.40 ± 23.82 versus
75.62 ± 28.14 pg/ml in TNF-α, P = 0.792; 14.12 ± 2.91
versus 1.79 ± 1.12 pg /ml in VEGF, P = 0.001 respect-
ively). Furthermore, IL-6 presented the strongest ex-
pression in separate HCC groups: HCC-HBV group
versus HG (15.57 ± 3.85 versus 0.46 ± 0.10 pg/ml in
IL-6, P < 0.001; 240.39 ± 95.39 versus 9.83 ± 3.26 pg/ml
in IL-27, P = 0.018; 24.74 ± 9.36 versus 1.76 ± 1.49 pg/
ml in TNF-α, P = 0.018; 19.02 ± 5.39 versus 0.40 ±
0.07 pg/ml in VEGF, P = 0.001 respectively) and
CH-HBV group (15.57 ± 3.85 versus 6.55 ± 4.31 pg/ml
in IL-6, P = 0.174; 240.39 ± 95.39 versus 139.61 ±
40.51 pg/ml in IL-27, P = 0.504; 24.74 ± 9.36 versus
4.57 ± 1.49 pg/ml in TNF-α, P = 0.124; 19.02 ± 5.39
versus 2.15 ± 1.58 pg/ml in VEGF, P = 0.046 respect-
ively); HCC-HCV group versus HG (23.96 ± 5.98 ver-
sus 0.46 ± 0.10 pg/ml in IL-6, P < 0.001; 325.98 ± 98.96
versus 9.83 ± 3.26 pg/ml in IL-27, P = 0.002; 119.77 ±
53.11 versus 1.76 ± 1.49 pg/ml in TNF-α, P = 0.030;
9.53 ± 2.77 versus 0.40 ± 0.07 pg/ml in VEGF, P = 0.002
respectively) and CH-HCV group (23.96 ± 5.98 versus
2.78 ± 1.06 pg/ml in IL-6, P = 0.001; 325.98 ± 98.96 ver-
sus 175.53 ± 44.12 pg/ml in IL-27, P = 0.169; 119.77 ±
53.11 versus 76.35 ± 28.52 pg/ml in TNF-α, P = 0.43;
9.53 ± 2.77 versus 1.65 ± 0.78 pg/ml in VEGF, P = 0.066
respectively); and HCC-NBNC group versus HG
(21.14 ± 9.16 versus 0.46 ± 0.10 pg/ml in IL-6, P <
0.001; 482.75 ± 353.68 versus 9.83 ± 3.26 pg/ml in IL-
27, P = 0.003; 16.05 ± 7.41 versus 1.76 ± 1.49 pg/ml in
TNF-α, P = 0.083; 10.09 ± 5.96 versus 0.40 ± 0.07 pg/ml
in VEGF, P = 0.001 respectively) (Figure 1).
Among four mediators, over-expression of IL-6 correlated
with deterioration of liver and tumor condition according
to the BCLC staging system
Of four mediators, higher IL-6 level not only presented
the strongest correlation with clinical factors in liver
Table 1 Baseline characteristics of healthy and chronic hepatitis (CH) and hepatocellular carcinoma (HCC) patients (N = 303)
Demographics Non-HCC group (n = 156) HCC group (n = 147)
Healthy group (n = 54) CH group (n = 102) HCC-NBNC (n = 13) HCC-HBV (n = 70) HCC-HCV (n = 64)
Age (yrs) (range) 42.87 ± 13.35 (19–68) 50.20 ± 14.53 (19–78) 70.38 ± 8.85 (57–85) 60.00 ± 11.91 (30–86) 69.36 ± 9.71 (47–86)
Sex (Male) (%) 33 (61.10%) 61 (59.8%) 9 (69.20%) 56 (80.00%) 37 (57.80%)
Cirrhosis 0 13 (12.7%) 9 (69.20%) 47 (67.10%) 44 (68.80%)
Varices/Variceal
bleeding (%)




−/−/−/− −/−/−/− 0/3/7/3 14/10/24/22 13/19/17/15
Biochemical values
Albumin (g/dL) 4.44 ± 0.37 (3.5-5.0) 4.22 ± 0.51 (2.30-5.10) 3.32 ± 0.56 (2.40-4.50) 3.33 ± 0.73 (2.00-4.90) 3.26 ± 0.63 (2.00-4.80)
Bilirubin (mg/dL) 0.80 ± 0.23 (0.25-1.30) 1.04 ± 0.50 (0.42-4.11) 3.42 ± 5.58 (0.44-19.84) 2.77 ± 3.42 (0.38-16.47) 1.97 ± 2.52 (0.47-14.67)
Creatinine (mg/dL) 0.83 ± 0.20 (0.49-1.51) 0.86 ± 0.31 (0.43-2.62) 1.47 ± 0.86 (0.61-3.43) 1.10 ± 0.99 (0.42-6.95) 1.50 ± 1.60 (0.47-10.66)
AST (IU/L) 21.86 ± 6.28 (14–51) 66.58 ± 66.16 (12–463) 121.10 ± 162.74 (29.00-578.00) 166.88 ± 428.01 (23.00-3410.00) 106.51 ± 106.86 (25.00-488.00)
ALT (IU/L) 20.93 ± 7.16 (10–40) 86.07 ± 137.34 (13–1330) 48.38 ± 28.49 (5.00-103.00) 73.11 ± 105.62 (16.00-633.00) 72.14 ± 60.97 (10.00-366.00)
INR 0.96 ± 0.06 (0.86-1.18) 1.02 ± 0.08 (0.87-1.42) 1.25 ± 0.41 (0.85-2.21) 1.27 ± 0.46 (0.89-4.50) 1.15 ± 0.22 (0.86-2.20)
Platelet (103/uL) 245.46±57.22 (138–351) 179.01 ±58.24 (44–378) 163.62 ± 66.73 (22.00-265.00) 172.93 ± 91.03 (21.00-451.00) 124.50 ± 59.86 (18.00-323.0)
AFP (ng/mL) 2.78 ± 1.45 (1.0-8.02) 21.92±79.29 (0.99-611.11) 15421.25 ± 23754.14 (2.55-54001.0) 11119.34±20318.09 (2.05-54001.00) 5817.04 ±15840.43 (1.33-54001.0)
Virologic values












Figure 1 Four mediators’ expression in overall patients. Among four mediators, IL-6 presented strongest expression in HCC-total and separated
HCC groups as compared to the healthy (HG) or CH-total groups, *P < 0.05 defined as statistically significant.
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0.212; P = 0.016), Bilirubin (r = 0.280; P = 0.001), INR (r =
0.299; P < 0.001) (Table 2)—but also proved significant in
deteriorating patient condition, as per the BCLC scoring
system (terminal- versus early-stage HCC: 31.28 ±
7.14 versus 4.87 ± 1.66 pg/ml, P = 0.001; terminal- versusTable 2 Correlations between IL-6, IL-27, TNF-α, and VEGF wi
IL-6 IL-27
γ P γ
Age (years) 0.137 0.106 −0.016
Sex (F/M) 0.057 0.504 −0.052
Varices (−/+) 0.155 0.067 0.024
Variceal bleeding (−/+) 0.135 0.112 0.042
Albumin (g/dL) −0.383 <0.001* −0.098
Bilirubin (mg/dL) 0.280 0.001* 0.046
Creatinine (mg/dL) 0.181 0.032* −0.037
AST (IU/L) 0.212 0.016* 0.112
ALT (IU/L) −0.087 0.305 0.083
INR 0.299 <0.001* −0.064
Platelet (103/uL) 0.036 0.671 0.043
AFP (ng/mL) 0.261 0.002* 0.002
TNM Staging 0.370 <0.001* −0.109
BCLC Staging 0.471 <0.001* −0.028
(N = 147) *p < 0.05 defined as significantintermediate-stage HCC: 31.28 ± 7.14 versus 7.61 ± 2.84 pg/
ml, P = 0.003; advanced- versus early-stage HCC: 27.70 ±
7.83 versus 4.87 ± 1.66 pg/ml, P = 0.007; advanced- versus
intermediate-stage HCC 27.70 ± 7.83 versus 7.61 ± 2.84 pg/
ml, P = 0.019). Conversely, IL-27, TNF-α, and VEGF could
not present significance in each stage (Figure 2).th biochemical data in HCC patients
TNF-α VEGF
P γ P Γ P
0.855 −0.013 0.882 −0.078 0.363
0.538 −0.215 0.011* 0.023 0.788
0.775 0.058 0.495 0.152 0.075
0.625 0.215 0.011* 0.154 0.071
0.253 −0.031 0.717 −0.175 0.041*
0.590 0.161 0.060 −0.112 0.175
0.663 0.022 0.792 −0.074 0.391
0.208 0.092 0.300 0.020 0.819
0.329 0.087 0.305 −0.084 0.325
0.460 −0.095 0.269 0.160 0.063
0.619 0.016 0.857 0.002 0.985
0.977 0.120 0.157 0.123 0.152
0.200 −0.052 0.539 0.059 0.491
0.739 0.035 0.682 0.158 0.065
Figure 2 Four mediators’ expression in tumor severity. Among the four mediators, IL-6 and VEGF showed significant expressions in patients with
stages 3 or 4 HCC according to the classifications of TNM staging system (Figure 2A), but only IL-6 showed a significant difference in patients with
advanced or terminal-stage HCC according to classification of the BCLC staging system (Figure 2B), *P < 0.05 defined as significant.
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obviously 6-month mortality
Compatible with the above, over-expression of IL-6 cor-
related with mortality (<6-month versus ≥ 6-month sur-
vival: 29.66 ± 5.86 versus 12.23 ± 3.51 pg/ml, P = 0.012,
respectively) while portending 6-month mortality in
HCC-total cases (Table 3). By contrast, elevated IL-27,
TNF-α, or VEGF presented no significant correlation
with 6-month mortality (Figure 3).Liver preservation (Child-Pugh Classification) rather than
presence or absence of cirrhosis presented high
correlation with IL-6 over-expression
There was no link between four mediators with presence
or not of cirrhosis (19.80 ± 4.03 versus 19.50 ± 5.70 pg/
ml in IL-6, P = 0.966; 299.30 ± 79.70 versus 296.67 ±
135.87 pg/ml, P = 0.986 in IL-27; 74.13 ± 34.09 versus
46.98 ± 17.98 pg/ml in TNF-α, P = 0.596; 12.92 ± 2.80 ver-
sus 16.60 ± 6.82 pg/ml in VEGF, P = 0.555 respectively).
Table 3 Univariate cox regression model of baseline characteristics and 6-month mortality in hepatocellular carcinoma
(HCC) patients
Variable Parameter estimate SE of estimate Risk ratio (95%CI) P value
Demographics
Age (yrs) 0.011 0.016 1.011(0.981-1.043) 0.465
Gender (F/M) 0.532 0.392 1.702(0.790-3.668) 0.174
Varices (−/+) 1.490 0.381 4.438(2.101-9.373) <0.001*
Variceal rupture (−/+) 1.496 0.493 4.463(1.697-11.739) 0.002*
IL-6 (pg/mL) 0.015 0.007 1.015(1.002-1.028) 0.024*
IL-27 (pg/mL) 0.000 0.000 1.000(0.999-1.000) 0.204
TNF-α (pg/mL) −0.001 0.001 0.999(0.996-1.002) 0.401
VEGF (pg/mL) 0.034 0.013 1.034(1.009-1.060) 0.007*
AST (IU/L) 0.008 0.003 1.008(1.003-1.013) 0.003*
ALT (IU/L) 0.002 0.002 1.002(0.998-1.007) 0.337
Albumin (g/dL) −2.413 0.444 0.090(0.038-0.214) <0.001*
Bilirubin (mg/dL) 0.455 0.132 1.576(1.216-2.042) 0.001*
Cr (mg/dL) −0.014 0.132 0.986(0.761-1.278 0.914
INR 5.763 1.359 318.386(22.17-4572.329) <0.001*
Platelet (103/uL) 0.001 0.002 1.001(0.997-1.006) 0.576
AFP (ng/mL) 0.000 0.000 1.000(1.000-1.000) 0.001*
Cirrhosis (−/+) 1.131 0.422 3.10(1.357-7.083) 0.007*
BCLC staging 2.394 0.411 10.958(4.897-24.522) <0.001*
(N = 147) *p < 0.05 defined as statistically significant.
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Child-Pugh Classification and 6-month mortality in HCC-
total (IL-6: r = 0.365, P = 0.002; IL-27: r = 0.119, P = 0.325;
TNF-α: r = 0.059, P = 0.628; VEGF: r = 0.111, P = 0.363 re-
spectively; IL-6: r = 0.488, P < 0.001; IL-27: r = −0.109, P =
0.244; TNF-α: r = 0.038, P = 0.684; VEGF: r = 0.214, P =
0.022 respectively) as well as cirrhotic HCC cases (IL-6:
r = 0.376, P = 0.002; IL-27: r = 0.183, P = 0.139; TNF-α:
r = 0.143, P = 0.247; VEGF: r = 0.089, P = 0.480 respect-
ively; IL-6: r = 0.577, P < 0.001; IL-27: r = −0.036, P =
0.750; TNF-α: r = 0.085, P = 0.451; VEGF: r = 0.213, P =
0.059 respectively).
Rather than tissue p-STAT1, tissue p-STAT3 showed
predominant immunostain rate and correlated with
serum IL-6 expressions among four mediators in HCC
To elucidate clinical relationship between tissue p-STAT
proteins and serum mediators, we analyzed immunohis-
tochemical expression of p-STAT1 and p-STAT3 in 86
biopsies (52 CH and 34 HCC cases). Tissue p-STAT3
presented a predominant immunostain rate (≧10% im-
munostaining of hepatocytes) as compared to that of
p-STAT1 in all liver (51/86 versus 25/86, P < 0.001) and
CH (32/52 versus 19/52, P = 0.003) and HCC specimens
(19/34 versus 6/34, P = 0.024) (Figures 4A, B). Notably,
rising immunoreactivity levels of p-STAT3 instead of p-
STAT1 presented positive correlation with over-expressionof serum IL-6 rather than IL-27, TNF-α, and VEGF not
only in overall (p-STAT3: r = 0.354, P = 0.001; r = 0.116, P =
0.289; r = 0.125, P = 0.253; r = 0.175, P = 0.109 respectively)
(p-STAT1: r = −0.068, P = 0.531; r = −0.085, P = 0.438; r =
0.013, P = 0.907; r = −0.057, P = 0.606 respectively) but also
in HCC cases (p-STAT3: r = 0.501, P = 0.003; r = 0.052, P =
0.770; r = 0.019, P = 0.917; r = 0.096, P = 0.595 respect-
ively) (p-STAT1: r = 0.094, P = 0.597; r = −0.197, P = 0.264;
r = −0.093, P = 0.599; r = −0.118, P = 0.511 respectively)
(Figures 4C, D).Discussion
Biologic activities of functional mediators activating their
downstream special transducer are prominent in regulation
of inflammation and carcinogenesis. Still, the evidence of
biologic mechanisms and their interrelations with cancer
between functional IL-6, IL-27, TNF-α, and VEGF with
STAT protein is mostly limited to cell line or animal
models or non-HCC patients, and poorly understood in
liver disease, especially in diverse clinical-pathologic stages
of HCC.
The stimulation particularly by hepatitis B or C infection
can activate host immune mechanisms to drive serum
functional mediators that reflect inflammatory processes
and modulate liver regeneration. Indeed, our study only
found expressions of serum IL-6, IL-27, and TNF-α rather
Figure 3 Comparison of four mediators’ expression with patient’s mortality. Among four mediators, IL-6 presented strongest correlation with
6-month mortality in HCC patients (Figure 3), *P < 0.05 defined as significant.
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(Figure 1), which concurred with previous study: IL-6,
IL-27, or TNF-α playing an inflammatory role in regu-
lating hepatocyte proliferation and regeneration, and
VEGF playing a major role in pathogenesis of liver
cancer [17,18,20,22,23,26,28].
In addition to playing potential inflammation regulators
in IL-6, IL-27, and TNF-α, our study found these media-
tors with VEGF expressed strongly in HCC-total or separ-
ate HCC as compared to CH or HG cases (Figure 1),
which was compatible with prior studies: IL-6, IL-27, and
TNF-α could, like VEGF, play a pivotal role in carcinogen-
esis [12,16,24,26,28]. However, correlating their expression
with tumor severity (TNM staging system), only IL-6 and
VEGF presented a positive trend with tumor progression
(Figure 2A). In clinical settings, therapeutic standard and
survival prediction of HCC cases closely relates to levels
of the BCLC staging system, combining with tumor sever-
ity, liver function, and performance status. We found IL-6
instead of VEGF expressed obvious correlation not only
with tumor severity but also with deteriorating liver pres-
ervation (Figure 2B). This finding was also supported by
parameters associated with impaired liver function: AST
(r = 0.212; P = 0.016), albumin (r = −0.383; P < 0.001), bili-
rubin (r = 0.280; P = 0.001), INR (r = 0.299; P < 0.001), AFP(r = 0.261; P = 0.002), and creatinine (r = 0.181; P = 0.032)
significantly correlated with patient’s survival when IL-6
was over-expressed rather than other mediators (Figure 3,
Tables 2 and 3). Cirrhosis plays an important role in
pathogenesis of liver cancer and patient survival, which
also concurred with our result (Table 3). Yet we observed
presence or absence of cirrhosis in HCC patients not
reflecting expression of IL-6, IL-27, TNF-α, and VEGF.
This might be complicated and contribute to the liver
situation. While correlating among IL-6, IL-27, TNF-α,
and VEGF with Child-Pugh Classification and 6-month
mortality with presence or not of cirrhosis, only IL-6
over-expression strongly correlated with preservation
of liver function and 6-month mortality in HCC-total
(r = 0.365; P = 0.002, r = 0.488; P < 0.001 respectively) or
cirrhotic HCC (r = 0.376; P = 0.002, r = 0.577; P < 0.001
respectively). Findings can explain this discordance. It
yields clinical evidence of IL-6 linked with disease pro-
gression as compared with IL-27, TNF-α, and VEGF in
HCC cases.
Several signaling pathways mediating biologic effects of
these mediators, and STAT signaling pathway plays an es-
sential component linking cytokine signals to transcrip-
tion, inducing cell proliferation, protection from apoptosis,
tumorigenesis, and higher metastatic potential in diverse
Figure 4 Correlation between p-STAT1 and p-STAT3 with IL-6 expression. Immunostain expression of p-STAT1 and p-STAT3 in three identical
HCC tissues. Immunoreactivity exhibited in nuclei or cytoplasm of hepatocyte was designated Level I (<10%), II (≧10% to ≦25%), or III (≧25%)
(×400 magnifications) (brown cell as arrow shows positive immunostain) (Figure 4A). Tissue p-STAT3 presented a predominant immunostain
rate (≧10% immunoreactivities) unlike p-STAT1 in all specimens (Figure 4B left) and HCC specimens (Figure 4B right). Rising immunoreactivity
of p-STAT3 versus p-STAT1 positively correlated with over-expression of serum IL-6 rather than IL-27 and TNF-α and VEGF in all specimens
(Figure 4C) and HCC specimens (Figure 4D) (relationships of IL-27 and TNF-α and VEGF with p-STAT1 and p-STAT3 shown in Results), *P < 0.05
defined as significant.
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IL-6, IL-27, TNF-α, and VEGF with different clinical-
pathologic stages of HCC remains limited and warrants
further clarification. Both STAT1 and STAT3 proteins
have been implicated as essential components linking cy-
tokines signals to transcriptional events in pathogenesis of
liver disease [12,16,29]. To correlate STAT1 and STAT3
with their mediators, we examined CH and HCC tissues
to probe immunostain expressions. Tissues with p-STAT3
expressed a higher immunostain rate overall than p-
STAT1 in all liver (P < 0.001), or separate CH (P = 0.003)
and HCC specimens (P = 0.024) (Figures 4A, B), while ris-
ing immunoreactivity level of p-STAT3 reflected signifi-
cant correlation with IL-6 expression as compared to IL-
27, TNF-α, and VEGF expression in all patients (P = 0.001;
P = 0.289; P = 0.253; P = 0.109 respectively) or HCC (P =
0.003; P = 0.770; P = 0.917; P = 0.595 respectively) (Fig-
ures 4C, D). This confirmed a mechanism: IL-6 major
through p-STAT3 rather than p-STAT1 pathway affecting
severity of inflammation and carcinogenesis in liver dis-
ease, particularly in HCC patients [12,16,29]. This finding
was also concurred with previous study that STAT3 acti-
vated by exogenous IL-6 cytokine played a functional role
in cholangiocarcinoma development and associated with
patient’s survival, which belonged to hepatobiliary malig-
nancies [33].
Our study failed to model all participants’ liver tissue,
this limit based on ethical and safety considerations:
HCC patients with decompensated liver disease usually
have high hemorrhagic risk. While VEGF presented
strong correlation with 6-month mortality (Table 3), it
did not reflect as readily as IL-6, which might indicate
need for activation via other signal cascades like JAK/
STAT pathway in carcinogenesis [5,26,34]. Fluctuating
concentration of serum IL-6, IL-27, TNF-α, and VEGF
in the host might be argued, but these plasma molecules
assessed were not affected by time between blood sam-
pling and centrifuge, according to prior study [35].Conclusions
Take together, our findings clearly demonstrate serum
IL-6 rather than IL-27, TNF-α, and VEGF playing a def-
inite role in liver deterioration and tumor progression,
as well as further affecting HCC patient survival. The
mechanism of IL-6 biologic activity is chiefly through
activation of p-STAT3 instead of p-STAT1 protein in the
real world. From functional identification of IL-6/p-
STAT3 pathways, we believe ELISA detection of circulat-
ing IL-6 and immunostain of tissue p-STAT3 as biomarker
combined with current clinical biochemical data or images
can provide clinicians with useful references for prognosis.
Such an attractive immunotherapeutic strategy would re-
duce or prevent mortality in the future.Competing interests
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